“Bio-Betters” Could Be Good Business, But It’s Not For Genzyme – Termeer
Follow-on biologics that improve upon the originator drug could be developed into a good business but "that's not where we are choosing to go," Genzyme CEO Henri Termeer said at the Goldman Sachs Healthcare CEOs Unscripted conference Jan. 7
You may also be interested in...
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.